Showing 1 to 7 of 7 results
Germany and Austria First in EU to Offer Lecanemab for Early-Stage Alzheimer's
Starting September 1st, Germany and Austria will be the first EU countries to offer Lecanemab (Leqembi), a new Alzheimer's drug that slows disease progression in early stages, approved for patients with mild cognitive impairment and at most one copy of the ApoE4 gene.
Germany and Austria First in EU to Offer Lecanemab for Early-Stage Alzheimer's
Starting September 1st, Germany and Austria will be the first EU countries to offer Lecanemab (Leqembi), a new Alzheimer's drug that slows disease progression in early stages, approved for patients with mild cognitive impairment and at most one copy of the ApoE4 gene.
Progress
28% Bias Score
EU Approves Lecanemab for Early-Stage Alzheimer's; Strict Criteria Apply
The European Commission approved Lecanemab, a new Alzheimer's drug targeting amyloid plaques, for patients with minimal cognitive impairment and low ApoE4 gene copies; it offers a five-month delay in cognitive decline but is restricted due to potential side effects.
EU Approves Lecanemab for Early-Stage Alzheimer's; Strict Criteria Apply
The European Commission approved Lecanemab, a new Alzheimer's drug targeting amyloid plaques, for patients with minimal cognitive impairment and low ApoE4 gene copies; it offers a five-month delay in cognitive decline but is restricted due to potential side effects.
Progress
36% Bias Score
NHS to Re-evaluate Alzheimer's Drugs Amidst Cost and Efficacy Concerns
The NHS is reviewing its decision to block two Alzheimer's drugs, lecanemab and donanemab, which slow disease progression by up to 35 percent but cost approximately £1 billion annually, after public and advocacy group pressure.
NHS to Re-evaluate Alzheimer's Drugs Amidst Cost and Efficacy Concerns
The NHS is reviewing its decision to block two Alzheimer's drugs, lecanemab and donanemab, which slow disease progression by up to 35 percent but cost approximately £1 billion annually, after public and advocacy group pressure.
Progress
56% Bias Score
EMA Recommends Approval of Alzheimer's Drug Lecanemab
The European Medicines Agency (EMA) recommends approving Lecanemab, an Alzheimer's drug, for early-stage patients with mild cognitive impairment or mild dementia after a previous rejection due to safety concerns; the drug only slightly slows disease progression and is suitable for a small patient su...
EMA Recommends Approval of Alzheimer's Drug Lecanemab
The European Medicines Agency (EMA) recommends approving Lecanemab, an Alzheimer's drug, for early-stage patients with mild cognitive impairment or mild dementia after a previous rejection due to safety concerns; the drug only slightly slows disease progression and is suitable for a small patient su...
Progress
48% Bias Score
Lecanemab (Leqembi) Alzheimer Drug Launches in Germany
Germany and Austria are the first EU countries to launch Lecanemab, a new Alzheimer's drug, on September 1st, offering treatment to a limited subset of patients due to cost and eligibility restrictions.
Lecanemab (Leqembi) Alzheimer Drug Launches in Germany
Germany and Austria are the first EU countries to launch Lecanemab, a new Alzheimer's drug, on September 1st, offering treatment to a limited subset of patients due to cost and eligibility restrictions.
Progress
16% Bias Score
EU Approves First Alzheimer's Disease Treatment Targeting Disease Processes
The European Commission approved Lecanemab, a new Alzheimer's treatment targeting disease processes, for use in the EU; although effective in slowing progression in early stages for a small subset of patients, it is not a cure and its long-term effects remain uncertain.
EU Approves First Alzheimer's Disease Treatment Targeting Disease Processes
The European Commission approved Lecanemab, a new Alzheimer's treatment targeting disease processes, for use in the EU; although effective in slowing progression in early stages for a small subset of patients, it is not a cure and its long-term effects remain uncertain.
Progress
44% Bias Score
EMA Recommends Approval of Alzheimer's Drug Lecanemab
The European Medicines Agency (EMA) again recommends approving Lecanemab, an Alzheimer's drug, for early-stage patients after previously rejecting it due to safety concerns; a new analysis shows benefits outweigh risks in a specific patient subgroup; the drug is already approved in the USA.
EMA Recommends Approval of Alzheimer's Drug Lecanemab
The European Medicines Agency (EMA) again recommends approving Lecanemab, an Alzheimer's drug, for early-stage patients after previously rejecting it due to safety concerns; a new analysis shows benefits outweigh risks in a specific patient subgroup; the drug is already approved in the USA.
Progress
40% Bias Score
Showing 1 to 7 of 7 results